Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

MLA

van Ramshorst, Mette S., et al. “Trastuzumab in Combination with Weekly Paclitaxel and Carboplatin as Neo-Adjuvant Treatment for HER2-Positive Breast Cancer: The TRAIN-Study.” European Journal of Cancer, vol. 74, Mar. 2017, pp. 47–54. EBSCOhost, https://doi.org/10.1016/j.ejca.2016.12.023.

APA

van Ramshorst, M. S., van Werkhoven, E., Mandjes, I. A. M., Schot, M., Wesseling, J., Vrancken Peeters, M.-J. T. F. D., Meerum Terwogt, J. M., Bos, M. E. M., Oosterkamp, H. M., Rodenhuis, S., Linn, S. C., & Sonke, G. S. (2017). Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. European Journal of Cancer, 74, 47–54. https://doi.org/10.1016/j.ejca.2016.12.023

Chicago

van Ramshorst, Mette S., Erik van Werkhoven, Ingrid A.M. Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T.F.D. Vrancken Peeters, Jetske M. Meerum Terwogt, et al. 2017. “Trastuzumab in Combination with Weekly Paclitaxel and Carboplatin as Neo-Adjuvant Treatment for HER2-Positive Breast Cancer: The TRAIN-Study.” European Journal of Cancer 74 (March): 47–54. doi:10.1016/j.ejca.2016.12.023.